Committees in Congress have issued more than a dozen subpoenas to drug-makers for alleged price-hiking in the last 2 years, with members of the House and Senate collecting hundreds of thousands of documents on pricing strategies and marketing tactics. They’ve put pharmaceutical execs through more than 16 hours of public testimony. But an Associated Press review shows that pressure from Washington has done little to rein in drug prices.
The wire service’s examination of the list prices of 30 brand-name and generic medications showed that most have not budged after enduring federal scrutiny. While list prices for 5 of the drugs fell, prices for 2 of actually increased. More frequently, pressure from Congress did nothing to change the list price.
Get the full story at our sister site, Drug Delivery Business News
The post Report finds pressure from Congress does not budge drug prices appeared first on MassDevice.
from MassDevice http://ift.tt/2gnmFXA
Cap comentari:
Publica un comentari a l'entrada